Shionogi & Co Ltd 2017 IR
The report highlights Shionogi's financial and non-financial performance for fiscal 2016, showcasing record-high net sales of ¥338.9 billion and operating income of ¥108.2 billion. The company successfully overcame the 'Crestor cliff' through the growth of its anti-HIV treatments, Tivicay and Triumeq. Shionogi updated its Medium-Term Business Plan, Shionogi Growth Strategy 2020 (SGS2020), setting higher targets for growth, efficiency, and shareholder returns. Additionally, the company advanced its sustainability efforts, aligning with the UN Sustainable Development Goals, promoting antimicrobial stewardship, and implementing EHS initiatives to reduce CO2 emissions.
Company: Shionogi & Co Ltd
Sector: Health Care
Country: Japan
Year: 2017
Type: IR
Pages: 77
Shionogi & Co Ltd
Integrated Report
The report highlights Shionogi's financial and non-financial performance for fiscal 2016, showcasing record-high net sales of ¥338.9 billion and operating income of ¥108.2 billion. The company successfully overcame the 'Crestor cliff' through the growth of its anti-HIV treatments, Tivicay and Triumeq. Shionogi updated its Medium-Term Business Plan, Shionogi Growth Strategy 2020 (SGS2020), setting higher targets for growth, efficiency, and shareholder returns. Additionally, the company advanced its sustainability efforts, aligning with the UN Sustainable Development Goals, promoting antimicrobial stewardship, and implementing EHS initiatives to reduce CO2 emissions.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Apr 1, 2016 - Mar 31, 2017
Fiscal Year
2016
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Total Waste
Employees